Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients

Model scores of the 29,894 trials active now.

Model score 10% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 8% of the time (780 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2010-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 3.9% (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 186 (lowers risk) · Sponsor's track record
• Responsible party: not given (raises risk) · Design
• Phase: 2 (raises risk) · Design
• Number of arms: 5 (lowers risk) · Design
• Has a data monitoring committee: not given (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 13.1% (lowers risk) · Drug's FDA history
• Sponsor's past trials: 333 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: interferongenotypechronicprioralfa
  Phrases that lowered it: moderatedrugalcoholvisitevaluate
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Keywords listed: 5 (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients NCT00724776 · started 2008 · scored riskier than 31% of active trials completed
• Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection NCT00978497 · started 2009 · scored riskier than 12% of active trials completed
• Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C NCT01740089 · started 2011 · scored riskier than 10% of active trials completed
• Ribavirin Loading Dose or Priming and Concentration Targeting for HCV Genotype 1 NCT01226771 · started 2010 · scored riskier than 72% of active trials completed
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection NCT00851890 · started 2009 · scored riskier than 11% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.